Literature DB >> 24743914

Modelling technique, structural assumptions, input parameter values: which has the most impact on the results of a cost-effectiveness analysis?

Josephine Mauskopf1.   

Abstract

Mesh：

Year:  2014        PMID： 24743914     DOI： 10.1007/s40273-014-0157-7

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  11 in total

1.  Discrete event simulation: the preferred technique for health economic evaluations?

Authors:  Jaime J Caro; Jörgen Möller; Denis Getsios
Journal:  Value Health       Date:  2010-09-03       Impact factor: 5.725

Review 2.  A methodological review of models used to estimate the cost effectiveness of antiretroviral regimens for the treatment of HIV infection.

Authors:  Josephine Mauskopf
Journal:  Pharmacoeconomics       Date:  2013-11       Impact factor: 4.981

3.  Modelling the treated course of schizophrenia: development of a discrete event simulation model.

Authors:  Bart Heeg; Erik Buskens; Martin Knapp; Gerda van Aalst; Pieter J T Dries; Lieuwe de Haan; Ben A van Hout
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

Authors:  Gerd Laux; Bart Heeg; Ben A van Hout; Angelika Mehnert
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden.

Authors:  Per-Olof Thuresson; Bart Heeg; Benedicte Lescrauwaet; Karin Sennfält; Annette Alaeus; Aljoscha Neubauer
Journal:  Scand J Infect Dis       Date:  2011-01-13

Review 6.  Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.

Authors:  Nicolas M Furiak; Haya Ascher-Svanum; Robert W Klein; Lee J Smolen; Anthony H Lawson; William Montgomery; Robert R Conley
Journal:  Curr Med Res Opin       Date:  2011-01-25       Impact factor: 2.580

Review 7.  When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES.

Authors:  Jonathan Karnon; Hossein Haji Ali Afzali
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

8.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

9.  Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.

Authors:  Kit N Simpson; Rukmini Rajagopalan; Birgitta Dietz
Journal:  Adv Ther       Date:  2009-02-14       Impact factor: 3.845

10.  Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.

Authors:  K N Simpson; R W Baran; D Collomb; E J Beck; O Van de Steen; B Dietz
Journal:  J Med Econ       Date:  2012-06-07       Impact factor: 2.448
View more
  2 in total

Review 1.  Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges.

Authors:  Jordana K Schmier; Carolyn K Hulme-Lowe
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

Review 2.  Disparities in model-based cost-effectiveness analyses of tuberculosis diagnosis: A systematic review.

Authors:  T I Armina Padmasawitri; Gerardus W Frederix; Bachti Alisjahbana; Olaf Klungel; Anke M Hövels
Journal:  PLoS One       Date:  2018-05-09       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.